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CLINICAL FOCUS: PULMONARY AND RESPIRATORY CONDITIONS
REVIEW
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ABSTRACT
Non-ST-segment elevation myocardial infarction (NSTEMI) is defined as elevated cardiac biomarkers of
necrosis in the absence of persistent ST-segment elevation in the setting of anginal symptoms or other
acute event. It carries a poorer prognosis than most ST-segment elevation events, owing to the typical
comorbidity burden of the older NSTEMI patients as well as diverse etiologies that add complexity to
therapeutic decision-making. It may result from an acute atherothrombotic event (‘Type 1’) or as the
result of other causes of mismatch of myocardial oxygen supply and demand (‘Type 2’). Regardless of
type and other clinical factors, the hospital medicine specialist is increasingly responsible for managing
or coordinating the care of these patients. Following published guidelines for risk stratification and
basing anti-anginal, anticoagulant, antiplatelet, other pharmacologic therapies, and overall manage-
ment approach on that individualized patient risk assessment can be expected to result in better short-
and long-term clinical outcomes, including near-term readmission and recurrent events. We present
here a review of the evidence basis and expert commentary to assist the hospitalist in achieving those
improved outcomes in NSTEMI. Given that the Society for Hospital Medicine cites care of patients with
acute coronary syndrome as a core competency for hospitalists, it is essential that those specialists stay
current on optimal NSTEMI care.
Abbreviations: ACC: American college of cardiology; ACCOAST: comparison of prasugrel at the time of
diagnosis in patients with non-ST elevation myocardial infarction; ACS: acute coronary syndrome; ADP:
adenosine diphosphate; AHA: American heart association; ARB: angiotensin II receptor blocker; ASA:
acetylsalicylic acid; CABG: coronary artery bypass graft: CAD: coronary artery disease; CCTA: coronary
computed tomography angiography; cTn: cardiac troponin; CRUSADE: can rapid risk stratification of
unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA
guidelines; CURE: clopidogrel in unstable angina to prevent recurrent events; CURRENT: OASIS-7
clopidogrel and aspirin optimal dose usage to reduce recurrent events–seventh organization to assess
strategies in ischemic syndromes; ECG: electrocardiogram; ED: emergency department; ESRD: endstage
renal disease; ESC: European society of cardiology; FDA: food and drug administration; GRACE: global
registry of acute coronary events; LVEF: left ventricular ejection fraction; MACE: major adverse cardiac
event; MI: myocardial infarction; MVO2: myocardial oxygen demand; NSTEMI: non-ST-segment-elevation
myocardial infarction; NTG: Nitroglycerin; PCI: percutaneous coronary intervention; plato: platelet
inhibition and patient outcomes; PPI: proton pump inhibitor; PURSUIT: platelet glycoprotein IIb/IIIa in
unstable angina: Receptor Suppression Using Integrilin Therapy; RAAS: Renin-Angiotensin-Aldosterone
System; SHM: society of hospital medicine; STEMI: ST-segment-elevation myocardial infarction; TIMI:
Thrombolysis in Myocardial Infarction; TRITON-TIMI:trial to assess improvement in therapeutic outcomes
by optimizing platelet inhibition with prasugrel—thrombolysis in myocardial infarction
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Introduction
This review and commentary are intended to distill information
from evidence-based society guidelines, recent studies, and best
practices held among specialists in hospital medicine, emergency
medicine, and cardiology, to guide the hospitalist in managing
non-ST-segment-elevationmyocardial infarction (NSTEMI). In both
tertiary care and community hospitals, hospitalists are increasingly
responsible for some if not all of the medical management of
NSTEMI in a number of different clinical scenarios. Regardless of
setting, their goal is to support, advocate for and provide data-
driven risk stratification, and offer risk-driven treatment and evi-
dence-based continuity of care from the hospital admission to
discharge and follow up. We provide guidance to inform the
hospitalist’s evidence-based care in both the medical and inter-
ventional hospital cardiac care settings, and in both the upstream
(prior to diagnostic coronary angiography and evaluation of the
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coronary anatomy, if performed) and downstream (post-
angiographic) timeframes. Recommendations from current guide-
lines, pivotal clinical trials and recent observational studies, along
with expert consensus among the authors is offered.
Three hospital medicine specialists, two emergency medi-
cine specialists, one noninvasive cardiologist, one interven-
tional cardiologist, and one hospital pharmacist specializing
in thrombosis care collaborated on this article. A panel was
held to discuss individual perspectives on NSTEMI manage-
ment and create a cohesive set of recommendations to dis-
seminate for hospitalists’ use in varying practice environments.
The panel’s deliberations and the writing of this paper were
facilitated by the Hospital Quality Foundation (www.hospital
qualityfoundation.org) and supported by an unrestricted edu-
cational grant from AstraZeneca, whose representatives were
not involved in the discussions or the editorial process.
Definition of NSTEMI
The term ‘NSTEMI’ is defined as elevated cardiac biomarkers of
necrosis with the absence of persistent ST-segment elevation
(with the exception of posterior myocardial infarction) in the
setting of anginal symptoms or other acute event. It is distin-
guished from unstable angina, which has similar symptoms, by
laboratory criteria (i.e., elevation of cardiac troponin). There are no
diagnostic electrocardiographic criteria for NSTEMI. The term
‘acute coronary syndrome’ (ACS) encompasses STEMI, NSTEMI,
and unstable angina, and is characterized in the Fourth Universal
Definition of Myocardial Infarction as ‘the sudden imbalance
between myocardial oxygen consumption (MVO2) and demand’
[1]. This imbalance is typically rooted coronary atherosclerosis. The
primary risk factors for the development of atherosclerotic disease
include hypertension, dyslipidemia, diabetes mellitus, tobacco
use, and family history. While STEMI typically results from the
rupture or erosion of an atherosclerotic plaque that triggers local
inflammatory and prothrombotic activity in situ, resulting in occlu-
sion by platelet aggregation, thrombus formation, and infarction
of the muscle subtended by the affected vessel, NSTEMI results
from an imbalance in oxygen supply and demand by and delivery
to the myocardium, which can be caused by numerous patholo-
gies including acute coronary thrombosis.
In the United States, the median age of NSTEMI is 68 years
and occurs in an approximately 3:2 male:female ratio, though
some of the gender imbalance may be due to diagnostic bias
[2]. Myocardial infarction (MI) refers to the death of myocar-
dial cells due to ischemia. In order to fit laboratory require-
ments for myocardial injury, regardless of etiology, cardiac
troponin (cTn) levels must be elevated above the 99th per-
centile of normal [1]. When MI is due to atherothrombotic
coronary artery disease, with or without demonstrable ather-
osclerotic plaque disruption, the designation of ‘Type 1 MI’ is
used. Type 2 MI refers to myocardial injury resulting from
a disparity between myocardial demand and available oxy-
gen supply that is not directly due to acute thrombosis. There
are multiple possible causes of this imbalance, including
states of diminished myocardial perfusion (reduced supply)
such as hypotension or severe anemia, increased myocardial
oxygen demand such as severe hypertension or sustained
tachyarrhythmia, cardiac conditions such as heart failure
and Takotsubo syndrome, and systemic conditions such as
chronic kidney disease, hyperthyroidism, pulmonary embo-
lism, sepsis, and stroke (Table 1) [2]. The ‘Type 2’ designation
distinguishes an infarct from, for example, a stable low-grade
myocardial injury that occurs when an end stage renal dis-
ease (ESRD) patient on dialysis has a chronically elevated
troponin.
Elevated Troponin
No ECG Changes
Clinical suspicion of ischemia or ECG changes
(e.g., ST depression, T-wave inversion)
NSTEMI Treatment, Cardiology consult, 
evidence-based treatment
(ASA, anticoagulation, anti-platelet therapy, oral β-blocker, etc) Asses renal statusAssess volume status
Diminished
Normal
Hypovolemic
Replete; Address 
underlying cause
Address
underlying cause
Exploratory work-up may include:
CRP, drug screen, echo
Myocarditis Cardiomyopathy, PECocaine-induced vasospasm
Potential diagnoses include:
Figure 1. Initial evaluation pathway for elevated troponin.
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In part because of these co-morbidities and the insidious
nature of their effect on global physiology, patients with Type
2 MI as a whole have higher short-and long-term mortality
rates than Type 1 patients [1,3]. The former are less likely to
undergo interventional procedures or to be placed on evi-
dence-based anti-platelet therapy. Of note, women are more
likely to have a Type 2 versus a Type 1 MI [4]. Care is often
focused on stabilizing the presenting illness that cardiac
sequelae and their management may be deprioritized, or
their underlying illness presents contraindications to usual
cardiac management.
The patient experiencing an NSTEMI most often presents
to the emergency department (ED) for initial care, but there
is also a significant proportion of these patients that will
emerge from inpatient floors as a Type 1 event or as Type 2
resulting from comorbidities that lead to increased MVO2.
Hospitalists encounter these patients in a variety of settings.
Presenting symptoms in Type 1 NSTEMI may include chest
pain, pressure or tightness, nausea and/or vomiting, and
lightheadedness or palpitations; however, a patient may
not experience any ‘typical’ symptoms, especially in the
setting of certain comorbidities, such as diabetes and
advanced age [5]. The patient may even present with
another, potentially misleading chief complaint, such as
altered mental status or hyperglycemia, without any overt
or atypical ACS symptoms, and NSTEMI is discovered only
incidentally as part of the initial workup. A high index of
suspicion and proactive evaluation are important for the
practicing hospitalist in at-risk patients presenting with aty-
pical symptoms, in order to not miss an NSTEMI.
The hospitalist
Hospital medicine specialists comprise the fastest growing physi-
cian specialty in US healthcare. There are currently more than
60,000 hospitalists practicing in the US [6], and there are multiple
fellowships [7] available throughout the country through internal
medicine, family practice, and pediatrics that focus on further
enhancing the safety, quality, and effectiveness of care for hospi-
talists [8]. The hospitalist ‘model’ of an inpatient practice covered
in timed shifts has led to the development of other ‘ist’-suffixed
practices, such as those of ‘nocturnists,’who are hospitalists work-
ing only night shifts, ‘extensivists,’ hospitalists who also maintain
a limited (usually post-hospitalization follow-up) outpatient clinic
practice, and hospitalists that primarily or solely support one
specialty, such as cardiology, neurology, or orthopedic surgery.
This diversity of practice patterns for hospitalists is reflected in the
various settings in which a patient with NSTEMI might be encoun-
tered and managed or comanaged.
Hospitalists may provide care to patients with NSTEMI as:
● An initial consultant to the ED, whether as the primary
inpatient admitting physician, as facilitator of inter-
facility transfer (which may bypass the ED), or as
a ‘bridge’ to care by a cardiologist;
● As the ‘overseer’ of patients being dynamically risk-
stratified in a dedicated chest pain or observation unit;
● As a consultant to another inpatient service in a patient who
develops NSTEMI on the non-medical or post-operative
service;
● As a manager of ‘upstream’ care, overseeing risk stratifica-
tion and facilitating evidence-based, risk-driven medical
therapy including antithrombotic care, analgesia, blood
pressure and glycemic control, and overall stabilization;
and/or
● As a manager of ‘downstream’ care, caring for the
NSTEMI patient after angiography and/or intervention,
maintaining evidence-based care; and/or
● As the director of the discharge and follow-up process,
ensuring that evidence-based therapies are provided and
that the NSTEMI patient has adequate follow-up arranged.
This function enhances continuity of care and, if done well,
can have a positive impact on overall care quality and 30-
day readmission rates [9].
The hospitalist’s practice vis-à-vis NSTEMI care can also vary
dramatically based on the hospital setting (small vs large,
urban vs rural, teaching vs nonteaching), the extent of cardi-
ology back-up (especially the availability of diagnostic angio-
graphy and percutaneous coronary intervention (PCI)), and the
existence (or lack thereof) of protocols for care. In each of
these scenarios, the hospitalist can play a key role in timely,
high-quality, interdisciplinary care of the NSTEMI patient. In
fact, the Society for Hospital Medicine (SHM) denotes manage-
ment of ACS as a core competency for hospitalists [10,11].
Table 1. Non-ACS causes of elevated cardiac troponin.
CORONARY
Fixed severe coronary atherosclerosis
Coronary artery spasm
Coronary artery embolism
Coronary artery dissection
CARDIAC
Myocarditis/pericarditis
Sustained tachy- or bradyarrhythmia
Takotsubo syndrome
Drug toxicity (licit, such as neomycin, and illicit, such as cocaine)
Instrumentation/ablation
Defibrillation
Trauma (cardiac contusion)
Heart failure
Cardiomyopathy
VASCULAR
Severe hypertension
Acute ischemic stroke
Acute aortic dissection
PULMONARY
Acute respiratory failure
Acute pulmonary embolism
Severe pulmonary hypertension
SYSTEMIC
Advanced age
Sepsis
CKD
Burns
Severe exertion
Amyloid
Cirrhosis
Rhabdomyolysis
Hypotension/shock
Severe anemia
Post-operative status
Strenuous exercise
Stroke
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Evaluation of suspected type I MI
A 66-year-old male with history of hypertension and obesity
presents to the ED complaining of substernal pain that began
while he was shoveling snow. He has had this sensation before
with vigorous activity, but not with this extent of persistence.
He reports mild dyspnea, but no diaphoresis, nausea, or vomit-
ing. He had a ‘normal’ treadmill stress test 7 years ago. On
arrival, he reports waxing and waning substernal discomfort.
His pulse rate is 96 bpm, blood pressure is 176/112 mm Hg,
and respiratory rate is 20 bpm.
Evaluation and risk stratification
This patient is suspected of having a Type 1 MI, given his
presentation and his cardiac risk profile. Initial evaluation
must include a 12-lead electrocardiogram (ECG); the initial
ECG allows rapid exclusion of STEMI. An ECG without STEMI
but with new ST-segment depression or T-wave inversion
identifies a patient who is at higher risk of poorer outcomes.
The most common presenting ECG findings in NSTEMI, how-
ever, are sinus tachycardia and nonspecific ST-T wave changes.
Low-flow supplemental oxygen should be administered to
maintain the pulse oximetry at at least 90%. Laboratory tests
for electrolytes, glucose, renal function, and cardiac biomar-
kers should be promptly sent. This particular patient is not in
need of any immediate resuscitative measures, but his cardiac
rhythm and blood pressure trends should be monitored. In the
absence of any contraindications (allergy or active bleeding),
the patient should be given 324 mg of chewable aspirin (ASA).
Sublingual nitroglycerin (NTG) may provide both pain relief
and antihypertensive effect, but analgesic response to NTG
does not confirm angina, nor does the lack of a response
refute the presence of ACS [12]. Further pain relief can be
provided with small, incremental doses of morphine sulfate
(ACC/AHA Guidelines Level of Evidence IIb-B); larger doses
should be avoided [2].
It is now common for hospital laboratories to offer high-
sensitivity troponin assays, with the result that more subtle
elevations in troponin are detected, leading to a significant
increase in positive results. The challenge to the clinician is to
determine which of these abnormal markers is due to acute
myocardial ischemia, and which can be attributed to chronic
conditions or acute stress that secondarily impact the myocar-
dium. In fact, the majority of patients with an elevation in
troponin are from causes other than ACS [13].
Repeat troponin assays are vital in distinguishing ACS from
non-ACS causes of troponinemia, as there will be little to no
change in non-ACS elevated troponin between measurements.
If the patient with elevated troponin does not present with
typical or atypical ACS symptoms and has a reassuring ECG, it
is important to investigate other possible etiologies such as
sepsis, pulmonary embolism, hypertensive crisis, etc. Troponin
levels must also be evaluated in the context of the patient’s
renal function, as even minute quantities of troponin in the
bloodstream resulting from normal myocardial cell turnover
will accumulate if the kidneys are not clearing them.
The patient in Case 1 has nonspecific ST-T wave changes on
his initial ECG, an estimated creatinine clearance of 78 ml/min,
and an elevated level of troponin. A diagnosis of a Type 1
NSTEMI is made.
Risk stratification = treatment stratification
In NSTEMI, the defining elevation of cardiac troponin by itself
identifies a high-risk patient. In ACS management, high risk
substantiates the use of high-intensity therapy, so the tropo-
nin-positive patient is more likely to benefit from advanced
antithrombotic therapy and an invasive approach than from
conservative therapy [2]. Early stress testing is not a sound
option for the troponin-positive patient. Absent any contra-
indications to coronary angiography, if it is available, an inva-
sive diagnostic study would be recommended within 48 h by
both the current American College of Cardiology/American
Heart Association (ACC/AHA) and the European Society of
Cardiology (ESC) guidelines for NSTEMI care [2,14]. In many
smaller institutions in which hospitalists may provide care for
patients such as this, that would mandate a choice between
medical management only and transfer to another facility. It is
important to note that ‘upstream’ management of this patient
when destined for angiography is the same overall medical
management – whether the goal is preparing the patient for
angiography or bridging the patient to a safe hospital dis-
charge and later risk stratification during the post-MI period.
While the elevation in troponin in a patient with anginal symp-
toms identifies high risk, there are additional validated means of
assessing short- and long-term risk in NSTEMI. Such risk assess-
ment models can be used to substantiate the intensity of medical
therapy given in the early hours of NSTEMI care. While never
a substitute for sound clinical judgment, such models objectively
apply the relative impact of different risk factors on clinical deci-
sion-making. For example, the Timing of Intervention in Acute
Coronary Syndrome (TIMACS) trial provided evidence for early
(<24 h) versus delayed (>36 h) coronary angiography intervention
in ACS in high-risk patients, with a substantial reduction in the
secondary outcome of the study of death, MI, or refractory ische-
mia at 6 months in patients with a Global Registry of Acute
Coronary Events (GRACE) Risk Score >140 who underwent an
early invasive strategy [13,15]. The three most commonly used
tools for ischemic risk stratification are Thrombolysis in Myocardial
Infarction (TIMI) [16], GRACE [17], and Platelet Glycoprotein IIb/IIIa
in Unstable Angina: Receptor Suppression Using Integrilin Therapy
(PURSUIT) [18] (Table 2). These scores vary in ease of use and the
outcomes being predicted, but evaluate many overlapping para-
meters, and generally can be used bedside (for example, see
https://www.outcomes-umassmed.org/grace/acs_risk2/index.
html, accessed 10/14/19).
As antithrombotic agents and doses are selected, the
CRUSADE (Can Rapid Risk Stratification of Unstable Angina
Patients Suppress Adverse Outcomes with Early
Implementation of the ACC/AHA Guidelines) study provides the
clinician with a tool to evaluate post-NSTEMI patients for bleed-
ing risk [19]. The therapies that have the potential to benefit
NSTEMI patients in terms of ischemic outcomes – anticoagulants,
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anti-platelet medications, and angiography – all are associated
with an increase in bleeding risk, so these should be employed
with an eye toward improved benefit:risk balance in each case.
The CRUSADE Bleeding Risk Score can be used to guide medica-
tion selection (e.g., with a higher score, one might choose to
delay P2Y12 inhibition until after the coronary anatomy is defined)
or to guide interventionalmanagement once selected (e.g., using
a radial instead of femoral approach for vascular access). Using
validated ischemic and bleeding risk calculations together, espe-
cially in conjunction with an echocardiogram, can provide hospi-
talists with valuable guidance in managing NSTEMI patients
[20–22].
Initiation of treatment
The goals of pharmacological therapy of NSTEMI are to facil-
itate a decreased myocardial oxygen demand and/or
increased a myocardial oxygen supply and prevent further
thrombosis. Initial medical treatment comprises a multitarget
approach consisting of oxygen, antithrombotics, antianginal
drugs, and statins.
After administering full-dose ASA (ACC/AHA Guidelines
Level of Evidence I-A), sublingual NTG (I-C) if warranted, anti-
hypertensives as needed, the focus in on dynamic risk strati-
fication evaluating trending of cardiac enzymes, serial ECGs,
and serial physical examination for deterioration of cardiac
function. Acute management of hypertension, which in the
early setting may be provided by intravenous NTG given for
angina (I-B), should be followed per guidelines with oral beta-
adrenergic blockers (I-A) with or with angiotensin-converting
enzyme (ACE) inhibitors (I-B) [2]. The latter is particularly useful
in patients with diabetes or a history of heart failure (Class I-B)
[2]. Current guidelines recommend against intravenous beta
blockade in ACS patients, as they are potentially harmful when
risk for shock is present (Class III-B) [2].
If no resuscitation is needed, then upstream/medical care is
built upon that foundation. Antithrombotic therapy (compris-
ing anticoagulation and antiplatelet medications) form the
primary line of defense against further ischemic damage to
the heart. Anticoagulation in the upstream setting is usually
effectuated with unfractionated heparin. In the patient either
not destined for angiography or whose upstream interval may
be prolonged, enoxaparin and fondaparinux are reasonable
alternatives to heparin.
Advanced antiplatelet therapy – that is, beyond ASA –
targets the P2Y12 (or adenosine diphosphate (ADP) – receptor
on the platelet membrane. These drugs are potentially effec-
tive because ADP is a very potent activator of platelets. There
are three oral and one parenteral P2Y12 blockers approved by
the United States Food and Drug Administration (FDA): the
oral agents clopidogrel, prasugrel, and ticagrelor, and intrave-
nous cangrelor. Cangrelor is an intravenous P2Y12 inhibitor
that is unlikely to be in the hospitalist’s arsenal for NSTEMI
management with the potential exception of the patient with
poor gastrointestinal absorption intended for an early invasive
treatment [23]. Prasugrel is not indicated in the upstream
setting, due to excessive bleeding not offset by reduction in
major adverse cardiac events (MACE) among patients not
known to be going to coronary intervention [24–26]
The historical data for clopidogrel in upstream or medical
management derive from CURE (Clopidogrel in Unstable
Angina to Prevent Recurrent Events), in which a 300 mg load-
ing dose of clopidogrel (followed then by 75 mg once daily)
plus ASA was superior to ASA alone in reducing MACE [27].
The management strategy studied in CURE is now largely
outdated, as it preceded wide use of PCI and even troponin
measurement. In addition, most cardiologists now administer
an off-label loading dose of 600 mg clopidogrel. A formal
study of both higher doses of clopidogrel and ASA in
CURRENT-OASIS-7 (Clopidogrel and Aspirin Optimal Dose
Usage to Reduce Recurrent Events-Seventh Organization to
Assess Strategies in Ischemic Syndromes) failed to demon-
strate superiority of the higher doses of clopidogrel and clearly
demonstrated excess bleeding risk attributable to higher
doses of ASA [28].
The current ACC/AHA NSTEMI Guidelines gives preference
to ticagrelor over clopidogrel [2]. Ticagrelor was studied vs
clopidogrel in the PLATO (Platelet Inhibition and Patient
Outcomes) study with all patients receiving upstream dosing
[29]. Ticagrelor has a more rapid and consistent onset and
offset of action compared with clopidogrel. In the NSTE-ACS
cohort of PLATO, the primary efficacy endpoint of MACE
showed a mortality advantage for ticagrelor without signifi-
cant differences in major bleeding between the two arms.
A dedicated secondary analysis showed that the ischemic
benefit was not impacted by the duration of the upstream
interval [30]. The benefits of ticagrelor were observed
Table 2. Parameters included in GRACE [34], TIMI [33], and PURSUIT [18]
risk scores, and CRUSADE bleeding risk score [30].
GRACE TIMI PURSUIT
CRUSADE
Bleeding
Age Y Y Y
Heartrate Y Y
Systolic BP Y Y
Cardiac Arrest Y
ST Change on ECG Y Y Y
Elevated Troponin Y Y
Killip Class Y
Cardiac Risk Factors Y
Known CAD Y Y
ASA use in 7 days Y
Severe Angina Y
Sex Y Y
Worst CCS-class in 6w Y
Signs of heart failure Y Y
Hematocrit Y
Renal Function Y Y
History of Diabetes Y
Risk levels as initially
validated
Low: 0–133
Intermed:
134–200
High: > 200
Low: 0–2
Intermed:
3–4
High: 5-7
Linear
0-18
Very low: < 20
Low: 21–30
Moderate:
31–40
High: 41–50
Very high: > 50
Predicts Death or (re)
MI in
hospital
and at 6
months
Death, (re)
MI,
revasc
within
30 days
Death
or
(re)MI
in 30
days
Major bleeding
BP = blood pressure; ST = ST-segment; ECG = electrocardiogram; CAD =
coronary artery disease; CCS = Canadian Cardiovascular Society Angina Grade
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regardless of revascularization performed during the first 10
days after randomization. These data notwithstanding, ticagre-
lor is a potent antiplatelet agent, and as with all antithrombo-
tics, a patient-specific benefit:risk analysis should be
conducted at the bedside, primarily to balance relative
ischemic risk with bleeding risk. The key factors in assessing
bleeding risk are age, prior bleeding history, and renal func-
tion; in a subanalysis of PLATO of ACS patients with chronic
kidney disease, ticagrelor compared with clopidogrel signifi-
cantly reduces ischemic end points and mortality without
a significant increase in major bleeding [31]. Should bleeding
risk preclude an early invasive approach, data suggest an
advantage for ticagrelor over clopidogrel in the medically
managed NSTEMI patient [32]. (the key factors to consider
are prior bleeding history, renal function, and age). Concern
for an angiographically determined need for coronary artery
bypass grafting (CABG) surgery mitigates against upstream
loading of advanced antiplatelet therapy, but in contemporary
practice near-term CABG is increasingly rare and surgeons are
generally more predisposed to proceed with surgery without
overt delay in order to avoid prolonged hospitalization.
Current guidelines suggest that clopidogrel and ticagrelor be
held for 5 days prior to elective CABG, and for 24 h prior to
urgent CABG [2].The recent promise of a specific reversal
agent for ticagrelor means that this concern may be substan-
tially ameliorated in the future [33]. Particularly in the NSTEMI
patient being managed medically, but also in the upstream
care of patients being invasively managed, hospitalists should
feel comfortable, in consultation with their cardiology collea-
gues, administering a loading dose of ticagrelor (180 mg,
followed then by 90 mg twice daily) to most NSTEMI patients.
Current observational data support this approach [34].
There are limited data to support the efficacy of high-dose
statin therapy in the early management of NSTEMI, but its
known anti-inflammatory activity, the lack of concern for
adverse events in the acute setting, and the need to continue
statin therapy after discharge all make this a reasonable
option for upstream/medical care of NSTEMI as managed by
the hospitalist.
Treatment team
While, as discussed above, the hospitalist may play either
a leading or supporting role in the management of NSTEMI,
a multidisciplinary approach is required to optimize and make
more consistent the care provided. Likewise, implementation
of an evidence-based NSTEMI treatment pathway improves
the care provided by all NSTEMI stakeholders [35]. The team
managing the NSTEMI patient may include emergency physi-
cians, hospitalists, cardiologists, nurses, pharmacists, and case
management. The hospitalist often has a crucial role to play as
the conductor among these services, and hospitalists should
therefore be well represented on pathway committees, quality
improvement projects, and other multidisciplinary groups
involved in NSTEMI management. Perhaps most importantly,
it often falls to the hospitalist to manage discharge planning
for the Type 1 NSTEMI, arranging outpatient medications,
cardiac rehabilitation, and follow-up, possibly in coordination
with case management. This is a crucial step in the treatment
process that involves not only knowledge of and compliance
with evidence-based guidelines [24,36], but also an accurate
assessment of the patient’s health literacy [37].
Case: evaluation of suspected type 2 MI
A 77-year-old female is an inpatient on the general surgical floor,
having been admitted for diverticulitis. She had been sent in
from her assisted living facility for abdominal pain and fever. In
the ED, she was mildly hypotensive, tachycardic, and febrile. She
was started on intravenous fluids and empiric broad-spectrum
antibiotics. A computed tomography scan demonstrated acute
diverticulitis with concern for perforation. She was admitted and
underwent resection of 22 inches of colon the same night. On
postoperative day 2, she was noted to have continued hypoten-
sion and tachycardia. Laboratory abnormalities included tropo-
nin elevation from baseline, and the covering hospitalist was
asked to evaluate her. She had no complaints of chest discomfort
or shortness of breath, and clinically she had no overt signs of
heart failure. She had no known prior diagnosis of, or evaluation
for, coronary artery disease.
Evaluation and differential diagnosis
In this case, the task of the consulting hospitalist is substantially
different from that in the first case. There is limited clinical
concern for a Type 1 NSTEMI, but evaluation, risk stratification,
differential diagnosis, and next therapeutic steps are nonetheless
driven by the elevated troponin level. This patient has sustained
myocardial damage, although probably not as the result of acute
plaque rupture. Nonetheless, elevated troponin levels indicate
a high risk of mortality even without ACS. The hospitalist is faced
with these issues, in order of priority: (1) stabilize the patient and
support the blood pressure, considering transfer to a critical care
setting if the patient’s condition does not rapidly improve; (2)
evaluate the patient’s baseline issue (concern for intra-
abdominal sepsis or hemorrhage); and (3) evaluate the elevated
cTn level, thereby developing a differential diagnosis and plot-
ting next therapies (See Figure 1).
The finding of an elevated troponin level is an indicator of
poor prognosis, independent of comorbidity or the specifics of
the clinical situation [38–41]. It is therefore important for the
hospitalist to be familiar with other diagnoses associated with
an elevated troponin.
The abnormal laboratory value must first be interpreted in
the clinical context: that is, is there reasonable clinical suspi-
cion of ACS? If not, one must evaluate the patient for second-
ary explanations of an imbalance in oxygen supply and
demand to the cardiac myocytes. A possible ‘coronary but
not ACS’ explanation of an elevated troponin is, in fact, sup-
ply:demand mismatch due to flow across a fixed coronary
stenosis. The most common causes of elevated troponin out-
side the ACS setting are listed in Table 1 [1,42–44].
It is advisable for the managing or consulting hospitalist to
seek input from the cardiology service on patients with
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presumed non-ACS troponin elevation. A proper diagnosis for
such patients is Type 2 NSTEMI [3], but coronary angiography is
often not indicated. An optimal strategy for rapid evaluation of
these patients includes close-interval (e.g. every 2 h) trending of
troponin values and bedside transthoracic echocardiography.
Absence of regional wall motion abnormalities in a patient
such as the elderly post-operative female in the second case
makes it unlikely that angiography or aggressive cardiology
intervention will be helpful. This reinforces for the hospitalist
the need to obtain an echocardiogram, even when logistically
challenging, in such patients [45].
A careful history and physical examination must guide the
hospitalist in further diagnostic endeavors. In evaluating for
coronary disease, which of course can co-exist with other diverse
diagnoses, there may be a role for computed tomographic cor-
onary angiography (CCTA), especially if that study is available
and echocardiography is not [46]. CCTA can provide evidence for
or against critical CAD, with a high negative predictive value [13].
In the unstable patient in the Type 2 case, however, CCTA would
not be a reasonable option, and urgent echocardiography
should be pursued. In general, advanced anticoagulation and
antiplatelet therapy should not be empirically initiated in these
patients unless there is a strong suspicion of an active ACS
diagnosis [3]. It is worth noting, however, that this distinction
can be quite difficult; many patients with NSTEMI have only
nonspecific ST-T wave changes, particularly if they have
a history of left ventricular hypertrophy and hypertensive heart
disease and are tachycardic, or if they have superimposed elec-
trolyte abnormalities. While some other diagnoses, such as sepsis
or arrhythmias, may be readily apparent, others may not, and
therapy should be guided by the progress of the diagnostic and
risk-stratification process. A BNP (or NT-pro-BNP) assay may be
helpful in identifying heart failure- and pulmonary-related diag-
noses; D-dimer, with its high sensitivity and low specificity, may
have limited utility in supporting or refuting suspicion for pul-
monary embolism in the Type 2 MI patient. Other diagnostic
testing, including possible coronary angiography, is driven by
the patient’s co-morbidities and physical examination.
Downstream treatment and transition of care for
NSTEMI patients
For patients who have diagnosed with NSTEMI, whether sub-
jected to invasive management or not, both Joint Commission
Core Measures and society guidelines recommend a broad range
of treatments aimed at reducing the risk of another ACS event.
Prior to hospital discharge, the hospitalist should be focused on
restoring the patient to normal activities to the extent possible
and to use the new NSTEMI diagnosis to formulate a plan of care,
focusing particularly on lifestyle and risk factor modification. This
patient education by the hospitalist is imperative to reduce read-
mission, ensure long-term adherence, and improve outcomes.
Patients with NSTEMI represent a high-risk cohort in whom sec-
ondary cardiovascular disease prevention is likely to be particu-
larly effective, and this should be initiated prior to index hospital
discharge. Hospitalists in these cases are presented with an
opportunity to provide evidence-based care to manage both
existing disease and future risk with pharmacologic treatments
and lifestyle modification. Discharge medications should gener-
ally include an anti-ischemic medical regimen (nitrates, beta-
blockers, calcium channel blockers) and antithrombotic medica-
tions applicable to the inpatient therapy. In most cases, this
includes dual antiplatelet therapy. Prognostic benefits have also
been shown for continued therapywith statins and, especially for
diabetics and those with a left ventricular ejection fraction (LVEF)
of 40% or less, an inhibitor of the renin-angiotensin-aldosterone
system. Lifestyle modification guidance such as smoking cessa-
tion support, increased activity as tolerated, and nutritional coun-
seling are helpful as well, and should be initiated at discharge. In
addition, a pre-discharge echocardiogram and fasting lipid panel
should be obtained.
A secondary goal for the hospitalist managing these discharges
is to reduce the likelihood of 30-day readmissions. A 2018 study of
such readmissions using the National Readmission Database 2014
identifying patients with a primary diagnosis of NSTE-ACS using
ICD9 coding found that of 300,269 patients admitted with NSTE-
ACS; 13.4% were readmitted within 30 days [47]. The most com-
mon cause of readmission was heart failure (15.6%), followed by
a recurrent MI (10%). Predictors of increased readmissions
included age ≥75 years, female gender, kidney disease, length of
stay ≥5 days, and complications during the index admission such
as acute kidney injury andmajor bleeding. Factors associated with
a lower risk of readmission included care in a teaching hospital
and performance of PCI on the index admission.
The hospitalist should liaise with all available resources,
including the cardiology service. Involvement of case manage-
ment for the entire hospital stay can help with increased
compliance as it allows more time for insurance approval of
various post-discharge recommendations, and addresses indi-
vidual barriers to care.
In planning for hospital discharge, guidelines recommend
assignment to cardiac rehab, which is followed by the inpatient
team 75.9% of the time post NSTEMI, but only 50% of those
patients referred for cardiac rehab actually enroll and participate
[48]. Lack of insurance coverage may be a limiting factor. The
quality and performance measures for cardiac rehab are available
online [48–52]. Smoking cessation counseling and a clinical nutri-
tion evaluation, when appropriate, should be arranged prior to
discharge. Such behavioral interventions are much more likely to
be successful when patient education techniques that account for
the patient’s and family’s health literacy are considered [37]. The
hospital setting after NSTEMI offers an ideal ‘teachablemoment’ in
which to educate patients and families and reinforce the educa-
tion daily under the care of the hospitalist. Time is usually not an
issue for either the hospitalist or the patient while in inpatient
status. Patient education should also focus on the symptoms of
potential recurrent ACS and the appropriate use of nitroglycerin
should such symptoms occur. A pneumococcal vaccine and an
influenza vaccine (if seasonally appropriate) should also be admi-
nistered, if needed, prior to discharge.
Follow-up after discharge is essential for good short- and
long-term outcomes. We recommend a follow-up phone call
(perhaps from either the hospitalist or a hospital pharma-
cist) within 72 h of discharge, and an in-person follow-up
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visit with cardiology or the patient’s PCP within 7 days.
Delays in follow-up are associated with poorer outcomes
and poorer patient medication adherence [24].
Communication between the hospitalist and the follow-up
physician (cardiologist or PCP) is imperative to establish and
maintain continuity of care.
Initiation of evidence-based post-discharge pharmaceutical
therapy provides optimal secondary prevention and reduces
the likelihood of early readmission of the NSTEMI patient. In
many facilities, the hospitalist plays a primary role in assuring
these guidelines are followed. Per ACC/AHA Guidelines, the
following therapies should be instituted at discharge unless
specifically contraindicated [2]:
● Antithrombotic therapy is a mainstay of secondary pre-
vention for ACS, and, if applicable, is a first line of
defense against in-stent thrombosis.
● ASA should be continued indefinitely at a dose of
81 mg per day (I-A).
● Ticagrelor or clopidogrel should be continued for 12
months after an NSTEMI, even if PCI was not per-
formed. If a stent was placed and the patient has
a low bleeding risk, prasugrel can be used as a P2Y12
inhibitor at the time of discharge (I-B). The ACC/AHA
Guidelines give preference to ticagrelor or prasugrel
for those patients treated invasively [2] (IIa-B).
● So-called ‘triple’ oral antithrombotic therapy (ASA +
P2Y12 + oral anticoagulant) can be considered in those
who have been treated for NSTEMI but also have atrial
fibrillation. The most informative recent trial addres-
sing this issue is AUGUSTUS (Apixaban Versus Vitamin
K Antagonist in Patients With Atrial Fibrillation and
Acute Coronary Syndrome and/or Percutaneous
Coronary Intervention) [51], which showed that in
patients with atrial fibrillation and a recent ACS or
PCI treated with a P2Y12 inhibitor, an antithrombotic
regimen of apixaban plus a P2Y12 agent, without
aspirin, resulted in similar rates of secondary ischemic
events with less bleeding than regimens that included
a vitamin K antagonist, a P2Y12 antiplatelet agents,
and aspirin) [51].
● Lipid management
● There is no demonstrable benefit to niacin or fish oil in
secondary prevention started acutely after NSTEMI.
● Statins are effective in reducing lipid levels and have
a presumed intravascular anti-inflammatory effect that
reduces the likelihood of recurrent ACS [52] (I-A). The
intensity of statin therapy should be individualized
based on desired effect and tolerance. Ezetimibe may
be a useful additional therapy [53]. The role of PCSK9
therapy is still being evaluated clinically and for cost-
effectiveness, but holds promise [54].
● Beta-adrenergic blockers
● Beta blockers decrease heart rate, contractility, and blood
pressure, resulting in decreased myocardial oxygen
demand, and should be provided as part of a secondary
prevention strategy after NSTEMI. Beta blockers increase
long-term survival after NSTEMI and should be initiated
during the ACS hospitalization and continued at dis-
charge (I-A). In patients with LVEF <0.40, beta blockers
are even more strongly recommended at the time of
discharge (I-A).
● Beta blockers should be used carefully with ACE inhibi-
tors or angiotensin-receptor blockers (ARBs) in patients
with heart failure, and renin-angiotensin-aldosterone
system (RAAS) blocking agents should be cautiously
added in patients with decompensated HF.
● The preferred agents in the NSTEMI setting are those
beta-blockers with no intrinsic sympathomimetic
activity, particularly sustained-release ß1 blockers
such as metoprolol succinate, bisoprolol, or carvedilol.
● ACE inhibitors and ARBs
● ACE inhibitors reduce mortality in patients with recent
MI, especially those with LV dysfunction (LVEF <0.40),
and in diabetic patients with normal LV function (includ-
ing patients with diabetes mellitus). Unless there are
specific contraindications, an agent in this class should
be prescribed at hospital discharge (I-A).
● Aldosterone inhibition
● Spironolactone should be added to the NSTEMI dis-
charge regimen in patients with a LVEF < 45% (I-A).
● Prophylaxis with proton pump inhibitors
● Proton pump inhibitors (PPIs) need not be routinely
used in patients on dual antiplatelet therapy. Those
with a history of gastrointestinal bleeding, those tak-
ing triple antithrombotic therapy, and those on high-
dose corticosteroid therapy are most likely to benefit
from prophylaxis with PPIs (IIa-C).
● SGLT-2 agents in type 2 diabetics
● There may be a role for these agents in the future
specifically in secondary prevention of ACS [55], but
they cannot be routinely recommended as yet.
Nonetheless, this is an active area of research and the
potential benefit of starting an SGLT-2 inhibitor in Type 2
diabetic patients (and perhaps even those who are not
diabetic) may soon become evident [56,57].
The problem of adherence
In spite of coordinated efforts on the part of the treatment
team aimed at ensuring optimal post-discharge care for the
NSTEMI patient, there may still be challenges that continue
after discharge. Adherence to DAPT and other therapies is
often suboptimal [24], and hospitalists must be both
attuned to anticipated adherence issues at the time of
discharge. Hospitalists and case managers must stay abreast
of available voucher programs, pill packs, smartphone
alarms, and the strategy of filling the first month (or, opti-
mally, 90 days) of pills at discharge (‘meds to beds’ pro-
gram) [58]. More liberal dispensing at discharge is often,
unfortunately, prohibited by insurers [59]. It is not clear
that use of generic drugs, when available, results in
improved adherence [60]. Adherence among post-NSTEMI
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patients continues to be a challenge, and even the most
innovative programs and devices do not necessarily lead to
improvements for patients [3,24,48,61,62].
Summary of recommendations
The hospital medicine specialist is ideally situated to ensure
evidence-based, risk-driven, timely care in acute NSTEMI and in
follow-up secondary prevention. Whether primarily or co-
managing the patient, the hospitalist has the time, expertise,
and experience to apply optimal care in this challenging cohort
of patients, many of whomhave extensive comorbidities and will
benefit from consistent care and targeted education. Aside from
performing the procedural aspects of diagnostic angiography
and catheterization laboratory or operating room-based therapy,
protocols and systems of NSTEMI care should be centered on the
hospitalist for managing the patient and as a resource for other
clinicians on the hospital care team and in the follow-up
environment.
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